Navigation Links
Glycominds Appoints Board of Directors Chairman
Date:10/18/2007

wed journals.

"Glycominds' glycan technology stands out as innovative and unique in comparison to the vast number of technologies and scientific approaches that I have seen throughout my years of involvement in the medical diagnostics industry," stated Dr. Even. "I believe that glycan technology has the potential to enhance autoimmune prognosis and the early detection of cancers. Glycominds is clearly pioneering the direction forward for adoption of glycan biomarkers in our industry and is greatly contributing to the visibility and international recognition of Israeli innovations and contribution in the field of medical in-vitro diagnostics."

About Glycominds, Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss based on hyper-coagulation caused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers.

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephra
'/>"/>

SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... health and nutritional food industry,engaged in the development, ... and raw cactus plants in the People,s,Republic of ... Mr. Ren,Hu will present at the upcoming Roth ...
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... in medicine. Although no significant achievements for curing disease have been achieved, ... approaches. By the year 2015, global market for gene therapy is projected ... ... 2008 -- Advancements in gene therapy have provided useful data, which has ...
Cached Biology Technology:China Yingxia to Present at Roth China Comes to Vegas Conference 2Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... the AIDS virus,s protein envelope once considered an improbable target ... most promising, new research by Dana-Farber Cancer Institute scientists indicates. ... the V3 loop, is an attractive vaccine target because immune ... multiple genetic subtypes of HIV-1, the virus that causes AIDS. ...
... "skin" of most every cell in your body, but the ... be rendered by many experimental techniques. A team of scientists ... and University of California, Irvine, recently developed a way to ... role of cholesterol within this boundary between the cell and ...
... Minnesota finalized a license agreement for CaSTT (Commerce and ... for technology transfer offices in universities and research institutions. ... consulting services that allow technology transfer offices to make ... and, in some cases, execute licenses from start to ...
Cached Biology News:Study identifies promising target for AIDS vaccine 2Study identifies promising target for AIDS vaccine 3Closer look at cell membrane shows cholesterol 'keeping order' 2